Quantification of two isomeric flavones in rat colon tissue using reverse phase high performance liquid chromatography

Crystal L. Whitted1, Victoria E. Palau1, Ruben D. Torrenegra2, Oscar E. Rodriguez3 and Sam Harirforoosh1*

Abstract

Background: Antineoplastic activity has been previously shown for two isomeric flavones, 5,7-dihydroxy-3,6,8-trimethoxy flavone (flavone A) and 3,5-dihydroxy-6,7,8-trimethoxy flavone (flavone B), against colon cancer cell lines (Thomas et al. in PLoS ONE 7:e39806, 5). Here, we present modified methods for the extraction and quantification of flavones A and B in rat colon tissue after intravenous dosing via high performance liquid chromatography, from the originally described procedure for extraction and quantification in rat plasma (Whitted et al. in J Chromatogr B Analyt Technol Biomed Life Sci 1001:150–155, 7).

Results: Modifications included tissue homogenization (1 g tissue: 2 mL water), filtration of the supernatant with a PVDF membrane, and the use of only one calibration curve to determine the concentration of each flavone in colon tissue. Good separation was achieved and representative equations were linear with $r^2 \geq 0.99$ for both flavones. Precision and accuracy for flavone A ranged from 0.88–24.03 and 109–116%. Precision and accuracy for flavone B ranged from 1.62–33.56 and 98–113%. Concentrations of $1639 \pm 601$ ng/g flavone A and $5975 \pm 2480$ ng/g of flavone B were detected in rat colon tissue 6 h post dosing.

Conclusions: Modifications to the extraction methods for flavone A and flavone B from rat colon tissue had good separation, precision, and accuracy.

Keywords: 5,7-Dihydroxy-3,6,8-trimethoxy flavone, 3,5-Dihydroxy-6,7,8-trimethoxy flavone, HPLC, Colon, Flavonoids, Cancer
distribution value of flavone B [7] compared to that of flavone A.

**Methods**

**Procedure to extract and purify flavones A and B**

The compounds were obtained as described before [5]. Briefly, flavone A was purified from dried flowers of *Gnaphalium elegans* extracted with chloroform using a silica gel chromatography column. Flavone B was purified from leaves of *Achyrocline bogotensis*, using chloroform, followed by crystallizations in hexane. The physical and spectroscopic properties of these compounds allowed their proper identification.

**Stock solution and standards**

Stock solutions of flavone A at a concentration of 100 µg/mL, prepared as described previously [7], and 25 µg/mL celecoxib (Toronto Research Chemicals; Toronto, ON, CA) were prepared with acetonitrile/water/acetic acid/triethylamine (60:40:0.2:0.05). Stock solutions of 100 µg/mL of flavone B, prepared as described previously [7], and 25 µg/mL diclofenac (MP Biomedicals, LLC; Solon, OH) were prepared with acetonitrile/water/acetic acid/triethylamine (70:30:0.2:0.05). All stock solutions were stored protected from light at 4 °C. HPLC grade acetonitrile, acetic acid, trimethylamine, and water were purchased from Fisher Scientific (Pittsburgh, PA). Flavone A or flavone B were mixed with polyethylene glycol 400 (Electron Microscopy Sciences; Hatfield, PA) for intravenous injection.

**Sample preparation**

Colon tissue was homogenized using a PowerGen 700 from Fisher Scientific (Pittsburgh, PA) in a 1:2 ratio with water (1 mg/2 mL). Serial concentrations for calibration curves (flavone A: 250–100,000 ng/g and flavone B: 1000–25,000 ng/g) were prepared. Briefly, 100 µL of blank homogenate was spiked with 100 µL flavone, 100 µL internal standard ([25 µg/mL celecoxib or diclofenac], and 200 µL of organic solvent (acetonitrile). The samples were vortex mixed before being centrifuged for 15 min at 3000×g. The supernatant was removed and filtered with a PDVF filter (0.45 µm) into a clean tube and evaporated using a Labconco vacuum concentrator (Kansas City, MO). Mobile phase (200 µL) was used to reconstitute the residue and 100 µL of sample was injected into the HPLC column. Analysis was conducted in triplicate.

**HPLC conditions and quantitation**

HPLC assays were performed using a Shimadzu liquid chromatography system (Shimadzu Scientific Instruments Inc., Columbia, Maryland, USA) with an ACE C18 (100 × 4.6 mm) (Aberdeen, Scotland) column. Mobile phases used for HPLC contained acetonitrile/water 60:40 (flavone A) and 70:30 (flavone B) with 0.2% acetic acid and 0.05% triethylamine. Detection wavelength was at 245 nm with a temperature of 30 °C. Flow rate was 0.4 mL/min with run times of 11 and 10 min, respectively. LC solutions program was used to collect and analyze the data.

**Animals and drug administration**

The methods described here were used to determine the concentrations of flavone A or flavone B in colon tissue collected from male Sprague–Dawley rats (Charles River Laboratories, Raleigh, NC, USA) used in a previous study [7]. Briefly, flavones were mixed in polyethylene glycol 400 and were administered by intravenous injection to deliver a 20 mg/kg dose of flavone A (n = 6) or flavone B (n = 6). Animals were euthanized under anesthesia 6 h post dosing. Colon tissue was collected and flash frozen using dry ice and stored at −80 °C until analyzed for the measurement of concentrations of flavones.

**Results**

Good separation was achieved (Figs. 1, 2) and the peak area ratios of flavone against internal standard were plotted in Excel to make the calibration curves (Fig. 3). Representative equation for flavone A concentrations 250–100,000 ng/g was \( y = 2E - 05x + 0.0029 \) and flavone B concentrations 1000–25,000 ng/g was \( y = 7E - 05x + 0.0531 \) with \( r^2 \geq 0.99 \). Three calibration curves were used to determine the precision (coefficient of variation—CV) and accuracy of the methods. Data is presented as mean ± standard deviation (Tables 1, 2). Analysis yielded 1639 ± 601 ng/g of flavone A and 5975 ± 2480 ng/g of flavone B in colon tissue (Fig. 4).

**Conclusion**

Modifications to the methods developed for extraction and quantification of flavone A and flavone B from rat colon tissue yield good separation, precision, and accuracy. The distribution of both flavones to the colon suggests that they would be good candidates for in vivo antitumor studies for colon cancer.
Fig. 1 Elution of flavone A from colon. HPLC chromatographs of a blank colon; b colon spiked with internal standard (celecoxib 25 µg/mL); c colon spiked with flavone A (100 µg/mL) and internal standard.
Fig. 2 Elution of flavone B from colon. HPLC chromatographs of a blank colon, b colon spiked with internal standard (diclofenac 25 µg/mL), c colon spiked with flavone B (100 µg/mL) and internal standard.
Abbreviations
Flavone A: 5,7-dihydroxy-3,6,8-trimethoxy flavone; Flavone B: 3,5-dihydroxy-6,7,8-trimethoxy flavone; HPLC: high performance liquid chromatography; PVDF: polyvinylidene fluoride.

Authors’ contributions
SH designed the experiments, analyzed the data, and wrote the manuscript. CLW perfumed the experiments, analyzed the data, and wrote the manuscript. VEP analyzed the data and wrote the manuscript. RDT and OER extracted and purified flavones A and B and wrote the manuscript. All authors read and approved the final manuscript.

Author details
1 Department of Pharmaceutical Sciences, Gatton College of Pharmacy, East Tennessee State University, Box 70594, Johnson City, TN 37614-1708, USA. 2 Universidad de Ciencias Aplicadas y Ambientales, Bogotá, Colombia. 3 Department of Environmental Engineering, Faculty of Engineering, Universidad El Bosque, Bogotá, Colombia.

Acknowledgements
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
The dataset supporting the conclusions of this article are available upon request from the first author manuscript.

Ethics approval and consent to participate
The study protocol (P-131001) was approved by the East Tennessee State University Committee on Animal Care, and conducted in facilities accredited by AAALAC according to guidelines in the Public Health Service Guide for the Care and Use of Laboratory Animals.

Funding
This study was funded by a grant from the East Tennessee State University Research Development Committee Major Grants Program. The funding body had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Received: 22 June 2016 Accepted: 20 December 2016 Published online: 07 January 2017

References
1. Lopez-Lazaro M. Flavonoids as anticancer agents: structure–activity relationship study. Curr Med Chem Anticancer Agents. 2002;2:691–714.
2. Kandaswami C, Lee LT, Lee PP, Hwang JJ, Ke FC, Huang YT, Lee MT. The antitumor activities of flavonoids. In Vivo. 2005;19:895–909.
3. Wang HK. The therapeutic potential of flavonoids. Expert Opin Investig Drugs. 2000;9:2103–19.
4. Kale A, Gavande S, Kotwal S. Cancer phytotherapeutics: role for flavonoids at the cellular level. Phytother Res. 2008;22:567–77.
5. Thomas CM, Wood RC 3rd, Wyatt JE, Pendleton MH, Torrenegra RD, Rodriguez OE, Harirforoosh S, Ballester M, Lightner J, Krishnan K, Ramsauer VP. Anti-neoplastic activity of two flavone isomers derived from Gnaphalium elegans and Achyrocline bogotensis. PLoS ONE. 2012;7:e39806.
6. LeJeune TM, Tsui HY, Parsons LB, Miller GE, Whitted C, Lynch KE, Ramsauer RE, Patel JU, Wyatt JE, Street DS, et al. Mechanism of action of two flavone isomers targeting cancer cells with varying cell differentiation status. PLoS ONE. 2015;10:e0142928.
7. Whitted CL, Palau VE, Torrenegra RD, Harirforoosh S. Development of reversed-phase high performance liquid chromatography methods for quantification of two isomeric flavones and the application of the methods to pharmacokinetic studies in rats. J Chromatogr B Analyt Technol Biomed Life Sci. 2015;1001:150–5.